JP2023036899A5 - - Google Patents

Download PDF

Info

Publication number
JP2023036899A5
JP2023036899A5 JP2022211496A JP2022211496A JP2023036899A5 JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5 JP 2022211496 A JP2022211496 A JP 2022211496A JP 2022211496 A JP2022211496 A JP 2022211496A JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
antibody
pharmaceutical composition
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022211496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023036899A (ja
JP7606501B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/017027 external-priority patent/WO2018145075A1/en
Application filed filed Critical
Publication of JP2023036899A publication Critical patent/JP2023036899A/ja
Publication of JP2023036899A5 publication Critical patent/JP2023036899A5/ja
Priority to JP2024218361A priority Critical patent/JP2025028191A/ja
Application granted granted Critical
Publication of JP7606501B2 publication Critical patent/JP7606501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022211496A 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 Active JP7606501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218361A JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling
JP2019542388A JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019542388A Division JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218361A Division JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023036899A JP2023036899A (ja) 2023-03-14
JP2023036899A5 true JP2023036899A5 (OSRAM) 2023-10-03
JP7606501B2 JP7606501B2 (ja) 2024-12-25

Family

ID=63040120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019542388A Active JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2022211496A Active JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019542388A Active JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Country Status (7)

Country Link
US (2) US20220213206A1 (OSRAM)
EP (1) EP3576793A4 (OSRAM)
JP (3) JP7231549B2 (OSRAM)
CN (1) CN110520158A (OSRAM)
AU (2) AU2018215673B2 (OSRAM)
CA (1) CA3049689A1 (OSRAM)
WO (1) WO2018145075A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534568B1 (ko) * 2016-07-22 2023-05-18 다나-파버 캔서 인스티튜트 인크. 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
AU2023324667A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
AU2013372331A1 (en) * 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
US9963513B2 (en) * 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
DK3189081T3 (da) * 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
HK1249532A1 (zh) * 2015-04-07 2018-11-02 F. Hoffmann-La Roche Ag 具有激动剂活性的抗原结合复合体及使用方法
CN110214152B (zh) * 2016-10-14 2025-06-13 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
JP7277363B2 (ja) * 2016-11-01 2023-05-18 ジェンマブ ビー．ブイ． ポリペプチド変異体およびその使用

Similar Documents

Publication Publication Date Title
JP2020505054A5 (OSRAM)
JP5246905B1 (ja) 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
JP2022504822A5 (OSRAM)
JP2018502050A5 (OSRAM)
CN113302205A (zh) 激动性肿瘤坏死因子受体超家族多肽
CA3095310A1 (en) Bi-functional proteins and construction thereof
JP2022505663A5 (OSRAM)
RU2017142008A (ru) Новые полипептиды
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
JP2022512043A5 (OSRAM)
JP2018504092A5 (OSRAM)
JP2020501550A5 (OSRAM)
US20260109748A1 (en) Modulation of dendritic cell lineages
RU2020118832A (ru) Биспецифические слитые полипептиды и способы их применения
JP2023159380A (ja) ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途
JP2024081718A5 (OSRAM)
KR20230148169A (ko) 항-pd-l1 모노클로날 항체 및 인터루킨-15 (il-15), 인터루킨-15 수용체 15 알파 또는 인터루킨-2와의 융합 단백질
EP4149627A1 (en) Agonistic tumor necrosis factor receptor superfamily polypeptides
JP2022530742A5 (OSRAM)
JP2024542235A5 (OSRAM)
JP2026048706A (ja) 新規なｉｌ１０アゴニストおよびその使用方法
JP2019518713A5 (OSRAM)
CA3017622A1 (en) Engineered trail for cancer therapy
CN114929745B (zh) Clec12a抗体片段序列和方法
WO2024017281A1 (zh) 多特异性抗体及其用途